Mian Chen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Mian Chen has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
Daizhou Zhang
Shandong Academy of Pharmaceutical Sciences, Key Laboratory of Biopharmaceuticals, Engineering Laboratory of Polysaccharide drugs, National‐Local Joint Engineering Laboratory of Polysaccharide drugs Postdoctoral Scientific Research Workstation Jinan China
1 shared publicationDandan Yuan
Shandong Academy of Pharmaceutical Sciences, Key Laboratory of Biopharmaceuticals, Engineering Laboratory of Polysaccharide drugs, National‐Local Joint Engineering Laboratory of Polysaccharide drugs Postdoctoral Scientific Research Workstation Jinan China
1 shared publication- Fei Liu
Shandong Academy of Pharmaceutical Sciences, Key Laboratory of Biopharmaceuticals, Engineering Laboratory of Polysaccharide Drugs, National-Local Joint Engineering Laboratory of Polysaccharide Drugs, Postdoctoral Scientific Research Workstation, Jinan 2501011, China
1 shared publication Jianting Hu
Shandong Academy of Pharmaceutical Sciences, Key Laboratory of Biopharmaceuticals, Engineering Laboratory of Polysaccharide drugs, National‐Local Joint Engineering Laboratory of Polysaccharide drugs Postdoctoral Scientific Research Workstation Jinan China
1 shared publicationLei Chen
Shandong Academy of Pharmaceutical Sciences, Key Laboratory of Biopharmaceuticals, Engineering Laboratory of Polysaccharide drugs, National‐Local Joint Engineering Laboratory of Polysaccharide drugs Postdoctoral Scientific Research Workstation Jinan China
1 shared publicationLinlin Niu
Shandong Academy of Pharmaceutical Sciences, Key Laboratory of Biopharmaceuticals, Engineering Laboratory of Polysaccharide drugs, National‐Local Joint Engineering Laboratory of Polysaccharide drugs Postdoctoral Scientific Research Workstation Jinan China
1 shared publication
Latest Publications
- 17 March 2023
- Published by Wiley in Journal of Biomedical Materials Research Part B: Applied Biomaterials
- Vol. 111 (7) , 1407-1418
Preparation, function, and safety evaluation of a novel degradable dermal filler, the cross‐linked poly‐γ‐glutamic acid hydrogel particles
Poly‐γ‐glutamic acid (PGA) is a naturally degradable hydrophilic linear microbial polymer with moisturizing, immunogenic, cross‐linking, and hydrogel water absorption properties similar to hyaluronic acid, a biomaterial that is commonly used as a dermal filler. To explore the development feasibility of cross‐linked PGA as a novel dermal filler, we studied the local skin response to PGA fillers and the effect of various cross‐linking preparations on the average longevity of dermal injection. Injection site inflammation and the formation of collagen and elastin were also determined. PGA hydrogel particles prepared using 28% PGA and 10% 1,4‐butanediol diglycidyl ether showed optimal filler properties, resistance to moist heat sterilization, and an average filling longevity of 94.7 ± 61.6 days in the dermis of rabbit ears. Local redness and swelling due to filler injection recovered within 14.2 ± 3.6 days. Local tissue necrosis or systemic allergic reactions were not observed, and local collagen formation was promoted. Preliminary results suggested that dermal injection of cross‐linked PGA particles appeared safe and effective, suggesting that cross‐linked PGA particles could be developed as a new hydrogel dermal filler.
- 17 March 2023
- Published by Wiley in Journal of Biomedical Materials Research Part B: Applied Biomaterials
- Vol. 111 (7) , 1407-1418
Preparation, function, and safety evaluation of a novel degradable dermal filler, the cross‐linked poly‐γ‐glutamic acid hydrogel particles
Poly‐γ‐glutamic acid (PGA) is a naturally degradable hydrophilic linear microbial polymer with moisturizing, immunogenic, cross‐linking, and hydrogel water absorption properties similar to hyaluronic acid, a biomaterial that is commonly used as a dermal filler. To explore the development feasibility of cross‐linked PGA as a novel dermal filler, we studied the local skin response to PGA fillers and the effect of various cross‐linking preparations on the average longevity of dermal injection. Injection site inflammation and the formation of collagen and elastin were also determined. PGA hydrogel particles prepared using 28% PGA and 10% 1,4‐butanediol diglycidyl ether showed optimal filler properties, resistance to moist heat sterilization, and an average filling longevity of 94.7 ± 61.6 days in the dermis of rabbit ears. Local redness and swelling due to filler injection recovered within 14.2 ± 3.6 days. Local tissue necrosis or systemic allergic reactions were not observed, and local collagen formation was promoted. Preliminary results suggested that dermal injection of cross‐linked PGA particles appeared safe and effective, suggesting that cross‐linked PGA particles could be developed as a new hydrogel dermal filler.